DOV KADMON to Prostate
This is a "connection" page, showing publications DOV KADMON has written about Prostate.
Connection Strength
0.801
-
Cytopathic effect of in situ gene therapy in prostate cancer. Hum Pathol. 2000 Jul; 31(7):866-70.
Score: 0.134
-
Differential expression of nuclear retinoid receptors in normal and malignant prostates. J Clin Oncol. 2000 Jan; 18(1):116-21.
Score: 0.129
-
Influence of the neural microenvironment on prostate cancer. Prostate. 2018 Feb; 78(2):128-139.
Score: 0.111
-
Synthesis and uptake of no-carrier-added 1-[11C]putrescine into rat prostate. Int J Nucl Med Biol. 1985; 12(5):349-52.
Score: 0.046
-
Effect of estrogen and androgen administration on alpha-difluoromethylornithine-enhanced putrescine uptake by the rat prostate. Prostate. 1985; 6(4):343-9.
Score: 0.046
-
Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol. 2004 Jan; 171(1):204-9.
Score: 0.043
-
Difluoromethylornithine enhancement of putrescine uptake into the prostate: concise communication. J Nucl Med. 1982 Nov; 23(11):998-1002.
Score: 0.039
-
Bilateral nerve grafting during radical retropubic prostatectomy: extended follow-up. Urology. 2001 Dec; 58(6):983-7.
Score: 0.037
-
Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol. 2001 May; 165(5):1554-9.
Score: 0.035
-
Retroviral transduction of transforming growth factor-beta1 induces pleiotropic benign prostatic growth abnormalities in mouse prostate reconstitutions. Lab Invest. 1996 Apr; 74(4):747-60.
Score: 0.025
-
Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech. 1995 Mar 01; 30(4):333-41.
Score: 0.023
-
Transforming growth factor-beta localization during mouse prostate morphogenesis and in prostatic growth abnormalities. World J Urol. 1995; 13(6):324-8.
Score: 0.023
-
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology. 1994 Mar; 134(3):1039-45.
Score: 0.022
-
Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system. Cancer Res. 1993 Oct 01; 53(19):4461-5.
Score: 0.021
-
Cancer-related axonogenesis and neurogenesis in prostate cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7593-603.
Score: 0.015
-
Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Hum Pathol. 2007 Nov; 38(11):1611-20.
Score: 0.014
-
Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology. 2004 May; 63(5):905-10; discussion 910-1.
Score: 0.011
-
Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data. Int J Radiat Oncol Biol Phys. 2004 Apr 01; 58(5):1520-9.
Score: 0.011
-
Prostatic cancer, acid phosphatase, creatine kinase-BB and race: a prospective study. J Urol. 1982 Oct; 128(4):735-8.
Score: 0.010
-
N-3-[18F]fluoropropylputrescine as potential PET imaging agent for prostate and prostate derived tumors. J Nucl Med. 1989 Jul; 30(7):1205-10.
Score: 0.004
-
2-[18F]fluoroputrescine: preparation, biodistribution, and mechanism of defluorination. Int J Rad Appl Instrum A. 1986; 37(7):607-12.
Score: 0.003